Does the media favor MRNA or INO?

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Moderna. MarketBeat recorded 6 mentions for Inovio Pharmaceuticals and 5 mentions for Moderna. Inovio Pharmaceuticals' average media sentiment score of 0.66 beat Moderna's score of 0.15 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inovio Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BBNX or INO?

In the previous week, Beta Bionics and Beta Bionics both had 6 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.66 beat Beta Bionics' score of 0.11 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inovio Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INO or DCTH?

In the previous week, Inovio Pharmaceuticals had 4 more articles in the media than Delcath Systems. MarketBeat recorded 6 mentions for Inovio Pharmaceuticals and 2 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.99 beat Inovio Pharmaceuticals' score of 0.66 indicating that Delcath Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INO or CLPT?

In the previous week, ClearPoint Neuro had 1 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 7 mentions for ClearPoint Neuro and 6 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.66 beat ClearPoint Neuro's score of 0.57 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ClearPoint Neuro 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inovio Pharmaceuticals (INO) Competitors

$1.31 +0.01 (+0.77%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$1.32 +0.01 (+1.15%)

As of 05/29/2026 07:32 PM Eastern

Compare

INO vs. MRNA, BBNX, DCTH, CLPT, and CV

Should you buy Inovio Pharmaceuticals stock or one of its competitors? MarketBeat compares Inovio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inovio Pharmaceuticals include Moderna (MRNA), Beta Bionics (BBNX), Delcath Systems (DCTH), ClearPoint Neuro (CLPT), and CapsoVision (CV).

How does Inovio Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Inovio Pharmaceuticals (NASDAQ:INO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

Inovio Pharmaceuticals has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	8.50	-$2.82B	-$8.15	N/A
Inovio Pharmaceuticals	$60K	1,796.23	-$84.95M	-$1.45	N/A

Moderna currently has a consensus target price of $35.73, suggesting a potential downside of 24.28%. Inovio Pharmaceuticals has a consensus target price of $4.50, suggesting a potential upside of 243.51%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

75.3% of Moderna shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Moderna. MarketBeat recorded 6 mentions for Inovio Pharmaceuticals and 5 mentions for Moderna. Inovio Pharmaceuticals' average media sentiment score of 0.66 beat Moderna's score of 0.15 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inovio Pharmaceuticals beats Moderna on 11 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Beta Bionics has higher revenue and earnings than Inovio Pharmaceuticals. Beta Bionics is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$110.24M	4.90	-$73.20M	-$1.51	N/A
Inovio Pharmaceuticals	$60K	1,796.23	-$84.95M	-$1.45	N/A

Inovio Pharmaceuticals has a net margin of 0.00% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

Beta Bionics presently has a consensus target price of $19.70, indicating a potential upside of 62.54%. Inovio Pharmaceuticals has a consensus target price of $4.50, indicating a potential upside of 243.51%. Given Inovio Pharmaceuticals' higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Beta Bionics has a beta of 3.29, meaning that its stock price is 229% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

In the previous week, Beta Bionics and Beta Bionics both had 6 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.66 beat Beta Bionics' score of 0.11 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beta Bionics beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Delcath Systems?

Inovio Pharmaceuticals (NASDAQ:INO) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Delcath Systems has a net margin of 0.62% compared to Inovio Pharmaceuticals' net margin of 0.00%. Delcath Systems' return on equity of 0.51% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
Delcath Systems	0.62%	0.51%	0.46%

In the previous week, Inovio Pharmaceuticals had 4 more articles in the media than Delcath Systems. MarketBeat recorded 6 mentions for Inovio Pharmaceuticals and 2 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.99 beat Inovio Pharmaceuticals' score of 0.66 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inovio Pharmaceuticals presently has a consensus price target of $4.50, indicating a potential upside of 243.51%. Delcath Systems has a consensus price target of $22.50, indicating a potential upside of 108.72%. Given Inovio Pharmaceuticals' higher probable upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Inovio Pharmaceuticals has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Delcath Systems has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,796.23	-$84.95M	-$1.45	N/A
Delcath Systems	$90.44M	4.11	$2.70M	$0.01	1,078.00

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Delcath Systems beats Inovio Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to ClearPoint Neuro?

Inovio Pharmaceuticals (NASDAQ:INO) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Inovio Pharmaceuticals has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -71.57%. ClearPoint Neuro's return on equity of -140.96% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

ClearPoint Neuro has higher revenue and earnings than Inovio Pharmaceuticals. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,796.23	-$84.95M	-$1.45	N/A
ClearPoint Neuro	$40.61M	9.36	-$25.54M	-$1.01	N/A

In the previous week, ClearPoint Neuro had 1 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 7 mentions for ClearPoint Neuro and 6 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.66 beat ClearPoint Neuro's score of 0.57 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Inovio Pharmaceuticals has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

Inovio Pharmaceuticals currently has a consensus target price of $4.50, indicating a potential upside of 243.51%. ClearPoint Neuro has a consensus target price of $18.00, indicating a potential upside of 42.07%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Inovio Pharmaceuticals and ClearPoint Neuro tied by winning 8 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to CapsoVision?

Inovio Pharmaceuticals (NASDAQ:INO) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Inovio Pharmaceuticals presently has a consensus target price of $4.50, indicating a potential upside of 243.51%. CapsoVision has a consensus target price of $8.50, indicating a potential upside of 25.37%. Given Inovio Pharmaceuticals' higher probable upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

CapsoVision has higher revenue and earnings than Inovio Pharmaceuticals. CapsoVision is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,796.23	-$84.95M	-$1.45	N/A
CapsoVision	$13.56M	24.98	-$25.32M	-$2.34	N/A

In the previous week, Inovio Pharmaceuticals had 5 more articles in the media than CapsoVision. MarketBeat recorded 6 mentions for Inovio Pharmaceuticals and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.87 beat Inovio Pharmaceuticals' score of 0.66 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Overall Sentiment
Inovio Pharmaceuticals	Positive
CapsoVision	Very Positive

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 2.3% of CapsoVision shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Inovio Pharmaceuticals has a net margin of 0.00% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
CapsoVision	-198.87%	N/A	-136.03%

Summary

Inovio Pharmaceuticals beats CapsoVision on 9 of the 16 factors compared between the two stocks.

Get Inovio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INO vs. The Competition

Export

Metric	Inovio Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$106.96M	$3.40B	$6.46B	$12.62B
Dividend Yield	N/A	2.28%	2.69%	5.24%
P/E Ratio	-0.90	18.88	21.31	26.28
Price / Sales	1,796.23	194.68	531.24	94.75
Price / Cash	N/A	124.68	43.65	57.38
Price / Book	18.71	7.27	10.60	7.32
Net Income	-$84.95M	$24.20M	$3.56B	$337.27M
7 Day Performance	-2.96%	4.11%	2.83%	3.58%
1 Month Performance	16.96%	6.66%	4.57%	5.71%
1 Year Performance	-35.47%	66.32%	37.66%	39.74%

Inovio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INO Inovio Pharmaceuticals	2.4568 of 5 stars	$1.31 +0.8%	$4.50 +243.5%	-38.5%	$106.96M	$60K	N/A	320
MRNA Moderna	1.4707 of 5 stars	$49.16 +0.3%	$35.73 -27.3%	+75.2%	$19.64B	$1.94B	N/A	4,700	Analyst Forecast
BBNX Beta Bionics	3.4013 of 5 stars	$9.43 -0.4%	$22.00 +133.4%	-21.1%	$419.98M	$100.25M	N/A	294	Positive News Analyst Forecast
DCTH Delcath Systems	2.4027 of 5 stars	$11.11 +0.4%	$22.50 +102.5%	-36.8%	$383.52M	$85.23M	1,111.00	60
CLPT ClearPoint Neuro	3.1117 of 5 stars	$11.72 +0.7%	$18.00 +53.6%	+5.8%	$357.03M	$40.61M	N/A	110	Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INO) was last updated on 5/30/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, BBNX, DCTH, CLPT, and CV

How does Inovio Pharmaceuticals compare to Moderna?

Summary

How does Inovio Pharmaceuticals compare to Beta Bionics?

Summary

How does Inovio Pharmaceuticals compare to Delcath Systems?

Summary

How does Inovio Pharmaceuticals compare to ClearPoint Neuro?

Summary

How does Inovio Pharmaceuticals compare to CapsoVision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, BBNX, DCTH, CLPT, and CV

How does Inovio Pharmaceuticals compare to Moderna?

Which has more risk & volatility, MRNA or INO?

Is MRNA or INO more profitable?

Which has higher valuation and earnings, MRNA or INO?

Do analysts recommend MRNA or INO?

Do institutionals & insiders hold more shares of MRNA or INO?

Does the media favor MRNA or INO?

Summary

How does Inovio Pharmaceuticals compare to Beta Bionics?

Do institutionals and insiders have more ownership in BBNX or INO?

Which has stronger earnings and valuation, BBNX or INO?

Is BBNX or INO more profitable?

Do analysts recommend BBNX or INO?

Which has more risk and volatility, BBNX or INO?

Does the media favor BBNX or INO?

Summary

How does Inovio Pharmaceuticals compare to Delcath Systems?

Is INO or DCTH more profitable?

Does the media prefer INO or DCTH?

Do analysts prefer INO or DCTH?

Which has more risk & volatility, INO or DCTH?

Which has preferable valuation and earnings, INO or DCTH?

Do institutionals & insiders believe in INO or DCTH?

Summary

How does Inovio Pharmaceuticals compare to ClearPoint Neuro?

Is INO or CLPT more profitable?

Which has stronger earnings & valuation, INO or CLPT?

Does the media prefer INO or CLPT?

Do institutionals and insiders believe in INO or CLPT?

Which has more volatility & risk, INO or CLPT?

Do analysts prefer INO or CLPT?

Summary

How does Inovio Pharmaceuticals compare to CapsoVision?

Do analysts prefer INO or CV?

Which has stronger valuation and earnings, INO or CV?

Does the media refer more to INO or CV?

Do insiders & institutionals have more ownership in INO or CV?

Is INO or CV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools